Skip to content

Study · Animal study (in vivo) · rabbit · 1988

3 results

Antipyretic properties of centrally administered alpha-MSH fragments in the rabbit.

Deeter LB, Martin LW, Lipton JM

Peptides1 Nov 1988Cited by 21 (Europe PMC)

PMID2854626 (opens in a new tab)DOI10.1016/0196-9781(88)90193-3 (opens in a new tab)PepBankPUB-02854626
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In febrile rabbits, intracerebroventricular alpha-MSH (11-13), the KPV tripeptide, reduced fever in a dose-related manner.

    In plain wordsIn rabbits with fever, KPV injected into the brain ventricles lowered fever, and more with higher doses.

    Peptide
    KPV
    Outcome
    DecreaseFever reduction
    Study

    rabbitn: not reported in source

    rabbits febrile after IV crude interleukin-1
    Outcome group
    Body temperature · Immune and inflammation
    Studied dose
    graded doses · intracerebroventricularAs given in this study (rabbit).

    Source sentences

    Summary
    Graded doses of alpha-MSH (11-13) (Ac LysProVal NH2), alpha-MSH (10-13) (Ac GlyLysProVal NH2), and alpha-MSH (8-13) (Ac ArgTrpGlyLysProVal NH2), were injected into the cerebral ventricles of rabbits made febrile by IV administration of crude interleukin-1. All three fragments reduced fever in a dose-related manner.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In febrile rabbits, alpha-MSH (11-13) was less effective at reducing fever than alpha-MSH (8-13) and more effective than alpha-MSH (10-13).

    In plain wordsIn rabbits, the KPV tripeptide lowered fever less than the 8-13 fragment but more than the 10-13 fragment.

    Peptide
    KPV
    Outcome
    MixedAntipyretic potency relative to alpha-MSH (10-13) and (8-13)
    Study

    rabbitn: not reported in source

    rabbits febrile after IV crude interleukin-1
    Comparator
    alpha-MSH (10-13) and alpha-MSH (8-13)
    Outcome group
    Body temperature · Immune and inflammation
    Studied dose
    graded doses · intracerebroventricularAs given in this study (rabbit).

    Source sentences

    Summary
    The (8-13) sequence was much more effective than the other two fragments, and the (10-13) portion was less effective than the (11-13) tripeptide.
    1 context sentence
    Summary · context
    Graded doses of alpha-MSH (11-13) (Ac LysProVal NH2), alpha-MSH (10-13) (Ac GlyLysProVal NH2), and alpha-MSH (8-13) (Ac ArgTrpGlyLysProVal NH2), were injected into the cerebral ventricles of rabbits made febrile by IV administration of crude interleukin-1.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In febrile rabbits, alpha-MSH (11-13) was less potent at reducing fever than full-length alpha-MSH (1-13).

    In plain wordsIn rabbits, the KPV tripeptide lowered fever less strongly than the full alpha-MSH molecule.

    Peptide
    KPV
    Outcome
    DecreaseAntipyretic potency relative to alpha-MSH (1-13)
    Study

    rabbitn: not reported in source

    rabbits febrile after IV crude interleukin-1
    Comparator
    alpha-MSH (1-13)
    Outcome group
    Body temperature · Immune and inflammation
    Studied dose
    graded doses · intracerebroventricularAs given in this study (rabbit).

    Source sentences

    Summary
    None of the fragments was as potent as alpha-MSH (1-13).
    1 context sentence
    Summary · context
    Graded doses of alpha-MSH (11-13) (Ac LysProVal NH2), alpha-MSH (10-13) (Ac GlyLysProVal NH2), and alpha-MSH (8-13) (Ac ArgTrpGlyLysProVal NH2), were injected into the cerebral ventricles of rabbits made febrile by IV administration of crude interleukin-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.